The Association committed a record $112.2 million across our research program in FY25, including nearly $80 million in grants for new scientific investigations. These grants represent proposals ranked highest by a multi-tier peer-review process in a highly competitive field. As of this report's publication, the Association — the world's leading nonprofit funder of Alzheimer's and dementia research — is investing $450 million in over 1,200 active projects in 56 countries, spanning six continents.

The Part the Cloud movement — founded and driven by philanthropist and longtime Association champion Mikey Hoag — stimulates and drives increased diversity in the global research pipeline. In FY25, Part the Cloud awarded $5 million toward pioneering gene therapy and gene editing projects, pushing the boundaries of what's possible in Alzheimer's treatment. Part the Cloud has raised nearly $90 million and funded 72 projects, and grant recipients have gone on to receive more than $1.6 billion in follow-on funding from the federal government and other sources.

The Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) is a two-year observational study designed to look at disease progression in adults under age 65 who are living with younger-onset Alzheimer's. To provide support and assistance for LEADS participants and their families, the Association held the fourth annual LEADS Family Meeting, with over 450 individuals attending in person or online. Sponsored in part by a National Institute on Aging (NIA) grant, the meeting informed and supported individuals and families living with younger-onset mild cognitive impairment and dementia via presentations, panel discussions and support options.

In collaboration with study leaders, the Association convened the International LEADS (iLEADS) collaboration, including study teams at the University College London in the United Kingdom, FLENI in Argentina, LUND University in Sweden, VU University Medical Center in the Netherlands, and Hospital de la Santa Creu i Sant Pau in Spain. The collaboration expands the understanding of younger-onset Alzheimer's disease beyond the United States.

The Association continued its partnership with the American Society of Neuroradiology on a funding initiative to spur innovation in the use of imaging and different types of imaging in Alzheimer's and other dementia research. In addition to funding four new projects this past year, the organizations committed to a continued partnership over the next three years aimed at the application of imaging technology in Alzheimer's and other dementia research.

The Alzheimer's Association International Conference (AAIC) is the premier annual conference for presentation and discussion of the latest Alzheimer's and dementia research. AAIC 2024 in Philadelphia attracted nearly 14,000 in-person and virtual attendees and included more than 5,400 scientific submissions.

Groundbreaking research presented at AAIC 2024 included clinical trial results of a GLP-1 agonist drug that suggest it can protect against brain shrinkage associated with dementia; how breathing wildfire smoke and eating too much processed meat are bad for brain health and may raise the risk of cognitive decline and dementia; and new Alzheimer's blood tests that are highly accurate and may improve recruiting for treatment trials and speed access to approved treatments.

Leading Alzheimer's and dementia researchers, clinicians and advocates from Latin America and around the world gathered for the 10th Alzheimer's Association International Conference (AAIC) Satellite Symposium in Lima, Peru, and online. Co-hosted by the Association and the Global Brain Health Institute, the event spotlighted the latest advances in dementia science and regionally driven approaches to care and prevention.

The Association hosted three AAIC Advancements meetings to bring together researchers around focused topics. Modernizing Diagnosis featured seven Asian countries in the scientific program and over 640 in-person and virtual attendees; Exploring Equity in Diagnosis attracted nearly 450 in-person and virtual attendees; and APOE & Lipid Biology saw a total of 790 attendees.

New guidance for the appropriate use of amyloid and tau positron emission tomography (PET) imaging was published by a workgroup convened by the Association and the Society for Nuclear Medicine and Molecular Imaging. The updated Appropriate Use Criteria are designed to help clinicians diagnose and manage people who are living with, or at risk for, cognitive decline.

The Association announced a strategic investment of $10 million in the Dementia Discovery Fund 2 (DDF-2), part of the world's largest family of specialized venture capital funds exclusively investing in companies that develop or enable novel therapeutics for dementia. This investment will drive progress across a spectrum of clinical trials, from seed and early-stage research to late-stage developments, and further strengthens the Association's robust global research funding portfolio.

Jointly managed by the Association and the NIA, the seventh annual NIA-AA Symposium — Enabling Precision Medicine for Alzheimer's Disease Through Open Science at AAIC 2024 featured an array of NIA-supported translational research programs that employ precision medicine principles and open-science practices. The symposium focused on understanding the complex causes of Alzheimer's and other dementia; developing the next generation of animal research models for Alzheimer's; identifying and validating new targets and biomarkers; advancing novel drug discoveries; and bringing precision medicine approaches to therapy development.

Hosted by the Association, CurePSP and the Rainwater Charitable Foundation, the Tau Global Conference 2025 brought together three major tau-focused conferences: Global Tau, EuroTau and CurePSP Neuro. The hybrid format provided a forum for members of academia, industry, philanthropy and government to collaborate and discuss key issues impacting the tau research community.

Led by the Association, which provided the initial funding, the Alzheimer's Network for Treatment and Diagnostics (ALZ-NET) is designed to collect routine clinical practice data from health care professionals caring for people living with Alzheimer's who are taking an FDA-approved disease-modifying treatment, with a goal of quickly and transparently sharing data and outcomes. ALZ-NET has over 240 clinical sites in various stages of the startup process and is also aligning with international registry efforts. At the end of FY25, ALZ-NET had over 100 fully activated sites and more than 2,200 patients enrolled nationwide.

Beyond ALZ-NET, the Association continued its global collaboration with ALZ-NET International to grow and connect real-world data platforms globally, providing opportunities to share resources, exchange ideas and amplify impact. ALZ-NET International collaborators meet quarterly to share updates and initiatives, with attendees spanning Australia, Germany, Iceland, Japan, the Netherlands, South Korea, Sweden, Turkey, the United Kingdom and the United States. A part of the ALZ-NET International initiative includes the Alzheimer's Association Funding Program for Global Real-World Data Platforms (ALZ-RWD). Projects funded through this program will develop, expand and align RWD platforms' infrastructure, data and impact globally. Two grants were awarded to Dr. Casper de Boer for the ABOARD Cohort at the Amsterdam University Medical Center in the Netherlands and to Dr. Christopher Rowe for the Alzheimer's Dementia Network (ADNeT) at the University of Melbourne.

The Association, the Global Brain Health Institute and the UK-based Alzheimer's Society announced the newest recipients of the Pilot Awards for Global Brain Health Leaders, a competitive funding initiative dedicated to fostering leadership in brain health and dementia care. Twenty-one awards were granted to projects tackling critical gaps in dementia diagnosis, care and support for underserved populations in 18 countries, including Zambia, Kenya, Poland, Egypt and Nepal.

The Alzheimer's Association Clinical Meaningfulness Workgroup developed recommendations and suggested language to help health care providers explain newly approved Alzheimer's treatments to people living with the disease and their caregivers. This workgroup published two papers in Alzheimer's & Dementia®: The Journal of the Alzheimer's Association focused on FDA-approved amyloid-targeting antibody therapies for early Alzheimer's that offer hope by slowing disease progression.

TrialMatch® is the Association's free service offering customized lists of clinical studies based on user-provided information. The TrialMatch database has over 3,000 engagements per month and includes more than 900 clinical trials. In FY25, TrialMatch was migrated to a new online platform to better meet the needs of research participants, health care providers and researchers, enabling the service to better match users to appropriate clinical studies and provide more robust data on the impact that TrialMatch has on connecting participants with research opportunities.

The Alzheimer's Association Research Roundtable (AARR) engages scientists from the pharmaceutical, biotechnology, diagnostics, imaging and cognitive testing industries worldwide in a precompetitive platform to discuss key areas in Alzheimer's science, with a mission of advancing the research, development and management of new treatments. The roundtable met twice in FY25. The fall 2024 meeting served as a forum for gathering industry perspectives and feedback on the topic Tau: Biology, Biomarkers and Therapeutics, ensuring that the new criteria inform research, clinical trial design and clinical care. The spring 2025 meeting, Alzheimer's Disease Stage 1 and 2: Biology, Diagnostics, and Treatment, provided a unique opportunity to address critical questions regarding screening, treatment, the timing of each and delivering clinically meaningful interventions.

Alzheimer's Association Business Consortium (AABC) members work to advance both the field of dementia research and the goals of its member organizations, providing leadership and direction to the group's areas of focus, which include collaborations, recognition, visibility, and knowledge and information sharing. More than 65 companies comprise the AABC, representing a wide range of research in dementia science, including artificial intelligence, diagnostics and therapeutics. The group held its annual meeting at AAIC 2024, attended by representatives of 17 companies and featuring presentations and a panel discussion that focused on strategic approaches and opportunities for fundraising.

The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART) is a diverse global network of over 14,000 (an increase of 1,000 over FY24) scientists, clinicians and dementia professionals in 125 countries. ISTAART professional interest areas (PIAs) — subgroups of researchers and clinicians who share common scientific interests — engaged with their members through 150 webinars, attracting over 5,300 live views; published 18 journal articles; and contributed 12 featured research sessions to AAIC 2024. In addition, the FY25 ISTAART Ambassador cohort included 39 ambassadors from 24 countries who delivered the Introduction to ISTAART presentation to over 1,100 scientists, clinicians and dementia professionals worldwide.

The Alzheimer's & Dementia journal family comprises four open access journals: Alzheimer's & Dementia: The Journal of the Alzheimer's Association (A&D), our flagship journal; Alzheimer's & Dementia: Diagnosis, Assessment and Disease Monitoring (DADM); Alzheimer's & Dementia: Translational Research & Clinical Interventions (TRCI); and the newest addition, Alzheimer's & Dementia: Behavior and Socioeconomics of Aging. The A&D family of journals aims to bridge knowledge gaps across a wide range of bench-to-bedside investigations in Alzheimer's, dementia and related topics. The impact factor, which is a measure of how frequently publications in the journal are referenced by other papers, are: A&D (11), DADM (4.4) and TRCI (6.8). (Behavior and Socioeconomics of Aging was launched at AAIC 2024.) Higher impact factors indicate a journal is more frequently cited and included in other research. Our flagship journal continues to be the top-ranked disease-specific journal in clinical neurology.

Funded by the Association, GAAIN is the first online platform to provide free, instant access to data normally restricted to a handful of Alzheimer's researchers, uniting a diverse and geographically distributed network of partners to foster discovery, collaboration and sharing. With more than 36,000 unique data attributes linking together over 70 research studies with nearly 750,000 participants, GAAIN serves as a one-of-a-kind resource for the global Alzheimer's and dementia community.

Multiple expert panels convened by the Association and representing primary and specialty care developed new clinical practice guidelines for comprehensive evaluation of patients who may have cognitive impairment or dementia due to Alzheimer's or a related disease. These efforts throughout FY25 culminated in the submission of one guideline manuscript, as well as a systematic review and the development of related tools for clinical use. The guidelines are critical to obtain timely and accurate diagnosis so that individuals and families are empowered and have the greatest autonomy to make the best decisions for themselves.

The World Dementia Council elected Association President and CEO Joanne Pike, DrPH, as its new chair. Pike will lead the organization's work to coordinate global efforts against dementia.